By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to accelerating the development of new treatments for pediatric cancer, has officially announced the appointment of Mark Zafra to its Board of Directors. Zafra, a highly accomplished executive with an extensive background in global supply chain management and procurement, joins the board at a pivotal time for the organization as it seeks to bridge the funding gap between laboratory research and clinical trials. Currently serving as the Chief Procurement Officer at LiveRamp, Zafra brings more than two decades of corporate leadership experience to the CureSearch mission, alongside a profound personal connection to the cause as a long-term cancer survivor.
The addition of Zafra to the governing body of CureSearch represents a strategic alignment of professional expertise and advocacy. His career has been defined by leading large-scale transformation initiatives at some of the world’s most prominent technology and healthcare companies, including Twitter, Allianz Fireman’s Fund, McKesson, HP, and Agilent Technologies. By integrating his sophisticated understanding of operational efficiency and strategic sourcing with the philanthropic goals of CureSearch, the organization aims to enhance its capacity for driving innovation in the pediatric oncology space.
A Career Defined by Strategic Transformation
Mark Zafra’s professional trajectory offers a blueprint for modern executive leadership in the realm of procurement and supply chain management. As the current Chief Procurement Officer at LiveRamp, he is responsible for overseeing global strategic sourcing, purchasing operations, corporate travel, and accounts payable. His role is central to the company’s operational health, ensuring that resources are allocated effectively to support global growth and technological innovation.
Prior to his tenure at LiveRamp, Zafra held senior leadership positions that required navigating complex global markets. At Twitter, he was instrumental in scaling procurement operations during periods of rapid expansion and volatility. His experience at McKesson, a global leader in healthcare supply chain management solutions and retail pharmacy, provided him with a unique vantage point on the intersection of logistics and healthcare—a perspective that is particularly valuable for a non-profit like CureSearch that operates within the medical research ecosystem.
Furthermore, his foundational years at HP and Agilent Technologies allowed him to master the intricacies of high-tech manufacturing and global distribution. These roles often involved managing multi-billion-dollar spends and spearheading digital transformation projects that streamlined organizational workflows. For CureSearch, Zafra’s ability to analyze complex systems and drive efficiency is expected to translate into improved operational strategies, helping the organization maximize the impact of every donor dollar.
The Intersection of Personal Experience and Philanthropy
While Zafra’s professional resume is formidable, his motivation for joining the CureSearch Board of Directors is deeply rooted in his personal history. Zafra is a cancer survivor, a fact that informs his perspective on the urgency of medical research and the necessity of patient-centric advocacy. This year marks a significant milestone in his journey: the 20th anniversary of his initial cancer diagnosis.
His transition from patient to survivor to advocate highlights a common trajectory among leaders in the non-profit sector, where lived experience serves as a powerful catalyst for systemic change. In his statement regarding the appointment, Zafra emphasized that his sense of responsibility is fueled by his own survival, driving a passion for ensuring that modern medicine can offer the same—or better—outcomes for the youngest and most vulnerable patients.
“It is with great enthusiasm and a deep sense of responsibility that I join CureSearch’s Board of Directors,” Zafra stated. “As a survivor myself, I am a passionate advocate for advancing cancer research and am honored by the opportunity to contribute my skills and experience to a mission that matters deeply to me.”
The Critical Landscape of Pediatric Cancer Research
The appointment of a seasoned procurement expert like Zafra comes at a time when the pediatric cancer landscape faces significant financial and structural hurdles. Despite being the leading cause of death by disease in children in the United States, childhood cancer research is historically underfunded compared to adult cancers. According to data from the National Cancer Institute (NCI), only about 4% of the federal budget for cancer research is dedicated specifically to pediatric oncology.
This funding disparity creates what researchers often call the "Valley of Death"—a gap where promising laboratory discoveries fail to transition into clinical trials due to a lack of financial backing and industry incentive. Because the market for pediatric drugs is smaller than that for adult treatments, pharmaceutical companies are often hesitant to invest the hundreds of millions of dollars required for drug development.
CureSearch for Children’s Cancer addresses this gap by focusing on "translational research." The organization identifies the most promising research projects and provides the necessary funding and project management to move them through the regulatory pipeline. Since its inception, CureSearch has been a vital link in the chain of survival, but the complexity of modern drug development requires increasingly sophisticated board oversight. Zafra’s background in sourcing and procurement is expected to assist the board in evaluating the efficiency of these research investments and the sustainability of the organization’s funding models.
Chronology of Leadership and Advocacy
The integration of Mark Zafra into the CureSearch leadership structure follows a deliberate timeline of professional achievement and personal milestones:
- 1990s – Early 2000s: Zafra builds a foundation in supply chain and procurement at HP and Agilent Technologies, developing expertise in global operations.
- 2004: Zafra receives his initial cancer diagnosis, beginning a personal battle that would eventually lead to a lifelong commitment to advocacy.
- Mid-2000s to 2010s: Zafra ascends to leadership roles at McKesson and Allianz Fireman’s Fund, gaining insights into the healthcare and insurance sectors.
- Late 2010s: Zafra leads procurement transformation at Twitter, managing global spend and infrastructure during a period of intense digital evolution.
- 2020s: Zafra joins LiveRamp as Chief Procurement Officer, further solidifying his reputation as a top-tier executive in the tech space.
- 2024: Zafra celebrates 20 years of cancer survivorship and is appointed to the CureSearch Board of Directors. He also commits to the CureSearch Ultimate Hike in Jackson, Wyoming, to raise funds for research.
The Ultimate Hike: A Physical and Financial Commitment
Beyond his role in the boardroom, Zafra is engaging in the organization’s grassroots fundraising efforts. He is scheduled to participate in the CureSearch Ultimate Hike in Jackson, Wyoming. The Ultimate Hike is the only national hiking program focused on ending childhood cancer, challenging participants to complete a rigorous long-distance trek in a single day.
For Zafra, the hike is more than a physical challenge; it is a commemorative act. By participating during his 20th year of survivorship, he is utilizing his personal network to raise critical funds that will be funneled directly into cutting-edge research. These funds support the CureSearch Acceleration Initiative, which targets the most difficult-to-treat pediatric cancers, such as brain tumors and relapsed neuroblastoma.
The Ultimate Hike program has historically been a significant revenue driver for CureSearch, fostering a community of "hikers" who are often parents of children with cancer, survivors themselves, or medical professionals. Zafra’s participation as a board member signals a "lead by example" approach, bridging the gap between high-level governance and the organization’s active donor community.
Official Responses and Organizational Impact
The leadership at CureSearch has expressed high expectations for the impact Zafra will have on the organization’s strategic direction. Jared Brancazio, the Chair of the CureSearch Board, highlighted the dual value Zafra brings to the table.
“Mark’s professional leadership and personal commitment to advancing cancer research make him an incredible addition to the CureSearch Board,” Brancazio said. “We’re honored to have him help guide our work and accelerate our impact.”
From a governance perspective, Zafra’s appointment is seen as a move toward greater organizational maturity. As non-profits face increasing scrutiny regarding their "overhead-to-impact" ratios, having a Chief Procurement Officer on the board provides a layer of fiscal rigor. Zafra can offer guidance on vendor management, contract negotiations, and resource optimization, ensuring that the maximum possible percentage of donations goes toward actual research rather than administrative costs.
Broader Implications for Pediatric Oncology
The inclusion of corporate heavyweights in non-profit boards is a growing trend that reflects the professionalization of the philanthropic sector. For CureSearch, this means moving beyond traditional fundraising and into the realm of venture philanthropy—an approach where donors act more like investors, demanding clear milestones, measurable outcomes, and efficient use of capital.
Zafra’s experience at companies like McKesson and HP—where "lean" operations and "just-in-time" supply chains are the norm—will be invaluable as CureSearch navigates the complexities of the FDA approval process and the global pharmaceutical supply chain. His insights could potentially help the organization better understand how to incentivize biotech companies to prioritize pediatric indications for new drugs.
Furthermore, Zafra’s presence on the board serves as a beacon of hope. In the world of pediatric cancer, where the focus is often on the immediate crisis of diagnosis and treatment, a board member who is a 20-year survivor provides a tangible example of the long-term goal: not just survival, but a thriving, productive life.
As CureSearch continues to fund the next generation of therapies—including CAR-T cell therapy, targeted biologics, and immunotherapy—the strategic guidance of leaders like Mark Zafra will be essential. His appointment is a testament to the organization’s commitment to excellence, ensuring that the fight against childhood cancer is managed with the same level of strategic precision as the world’s leading corporations. Through the combination of his professional acumen and his personal resilience, Zafra is poised to help CureSearch reach new heights in its mission to end childhood cancer once and for all.
